← United States · Coverage record
US · SEC FORM 4
Scribe Therapeutics, Inc.
SCTX · Nasdaq · CIK 0001853921 · Healthcare · Biotechnology
INSIDER SIGNAL
6 buyers · 8 purchase transaction lines · $71.3M gross purchase
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
What is holding the score back?
- ⚠ Role scores low · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
- ⚠ Purchase activity is becoming less recent
- ✓ Cluster breadth is broad · 4+ insiders
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.
Purchase breadth & concentration
Roles in the peak window: Chief Business Officer, Chief Financial Officer, Director, Director,Other; Director,TenPercentOwner,Other, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Latest recorded score
- 86.2
- 86.2
- 86.1
- 86.1
- 86.0
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -28.2%
- 3M
- —
- 6M
- —
- 12M
- —
Volatility & liquidity
- Volatility
- 137.6%
- Beta
- —
- Avg daily value
- USD 7.6M
Valuation
- Market cap
- USD 400.8M
- P/E
- —
Fundamentals
- Profit margin
- —
- ROE
- —
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 2,466,931
- Previous report
- 790,538
- Avg daily volume
- 689,637
- Days to cover
- 3.6
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-07-28 | Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC | Purchase (P) | Common Stock, par value $0.0001 per share | 7,905 | USD 18.25 | USD 144,266 | SEC filing ↗ |
| 2026-07-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Purchase (P) | Common Stock | 1,000,000 | USD 15.00 | USD 15,000,000 | SEC filing ↗ |
| 2026-07-27 | GORDON CARL L | Purchase (P) | Common Stock | 1,000,000 | USD 15.00 | USD 15,000,000 | SEC filing ↗ |
| 2026-07-27 | AH Bio Fund II, L.P.; AH Bio Fund III, L.P.; AH Equity Partners Bio II, L.L.C.; AH Equity Partners Bio III, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A | Purchase (P) | Common Stock | 333,333 | USD 15.00 | USD 4,999,995 | SEC filing ↗ |
| 2026-07-24 | Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC | Purchase (P) | Common Stock, par value $0.0001 per share | 2,383,333 | USD 15.15 | USD 36,115,495 | SEC filing ↗ |
| 2026-07-23 | Parrot David | Purchase (P) | Common Stock | 1,333 | USD 15.00 | USD 19,995 | SEC filing ↗ |
| 2026-07-23 | Lucas Svetlana | Purchase (P) | Common Stock | 3,000 | USD 15.00 | USD 45,000 | SEC filing ↗ |
Form 4 evidence
13 transaction lines in the latest 365-day window; 13 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-07-28 | Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC | Purchase (P) | Common Stock, par value $0.0001 per share | 7,905 | USD 18.25 | USD 144,266 | SEC filing ↗ |
| 2026-07-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Purchase (P) | Common Stock | 1,000,000 | USD 15.00 | USD 15,000,000 | SEC filing ↗ |
| 2026-07-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | C (C) | Common Stock | 348,825 | USD — | USD — | SEC filing ↗ |
Show recent Form 4 evidence (11 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-07-28 | Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC | Purchase (P) | Common Stock, par value $0.0001 per share | 7,905 | USD 18.25 | USD 144,266 | SEC filing ↗ |
| 2026-07-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Purchase (P) | Common Stock | 1,000,000 | USD 15.00 | USD 15,000,000 | SEC filing ↗ |
| 2026-07-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | C (C) | Common Stock | 348,825 | USD — | USD — | SEC filing ↗ |
| 2026-07-27 | GORDON CARL L | Purchase (P) | Common Stock | 1,000,000 | USD 15.00 | USD 15,000,000 | SEC filing ↗ |
| 2026-07-27 | GORDON CARL L | C (C) | Common Stock | 348,825 | USD — | USD — | SEC filing ↗ |
| 2026-07-27 | Doudna Jennifer A | C (C) | Common Stock | 12,511 | USD — | USD — | SEC filing ↗ |
| 2026-07-27 | AH Bio Fund II, L.P.; AH Bio Fund III, L.P.; AH Equity Partners Bio II, L.L.C.; AH Equity Partners Bio III, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A | Purchase (P) | Common Stock | 333,333 | USD 15.00 | USD 4,999,995 | SEC filing ↗ |
| 2026-07-27 | AH Bio Fund II, L.P.; AH Bio Fund III, L.P.; AH Equity Partners Bio II, L.L.C.; AH Equity Partners Bio III, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A | C (C) | Common Stock | 2,749,392 | USD — | USD — | SEC filing ↗ |
| 2026-07-24 | Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC | Purchase (P) | Common Stock, par value $0.0001 per share | 2,383,333 | USD 15.15 | USD 36,115,495 | SEC filing ↗ |
| 2026-07-23 | Parrot David | Purchase (P) | Common Stock | 1,333 | USD 15.00 | USD 19,995 | SEC filing ↗ |
| 2026-07-23 | Lucas Svetlana | Purchase (P) | Common Stock | 3,000 | USD 15.00 | USD 45,000 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | SCTX |
| CIK | 0001853921 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 13 transaction lines from 2026-07-23 to 2026-07-28 8 P purchase lines · 0 S sale lines · 5 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.